Cochemé Helena M, Murphy Michael P
University College London, Institute of Healthy Ageing, Department of Genetics, Evolution and Environment, Gower Street, London, WC1E 6BT, UK.
Curr Opin Investig Drugs. 2010 Apr;11(4):426-31.
Despite evidence that oxidative damage contributes to a wide range of clinically important pathologies, few antioxidants act as effective pharmaceuticals in vivo. The reasons for this therapeutic inefficacy include the challenge of targeting antioxidants to particular organs and intracellular locations, as well as the problem of matching the reactivity of antioxidants to the relevant damaging species in vivo. The difficulty of measuring antioxidant efficacy in vivo also makes the interpretation of results from clinical trials difficult. In this review, the challenges associated with antioxidant drug development are presented, and approaches to overcome these issues in order to design more effective therapeutic antioxidants are discussed.
尽管有证据表明氧化损伤会导致多种具有临床重要性的病理状况，但很少有抗氧化剂在体内能作为有效的药物发挥作用。这种治疗无效的原因包括将抗氧化剂靶向特定器官和细胞内位置的挑战，以及使抗氧化剂的反应性与体内相关损伤物种相匹配的问题。在体内测量抗氧化剂功效的困难也使得对临床试验结果的解读变得困难。在这篇综述中，介绍了与抗氧化剂药物开发相关的挑战，并讨论了克服这些问题以设计更有效的治疗性抗氧化剂的方法。
